24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
College Students Will Need COVID Tests Every 2-3 Days for Campus Safety: StudyAHA News: Sustained High Blood Pressure May Damage Brain VesselsAnother Side Effect of COVID-19 -- Lasting Hearing Problems?Pandemic Could Complicate Hurricane SeasonStudy Reveals How Coronavirus Travels IndoorsNew Study Sheds Doubt on Notion Kids Aren't COVID-19 SpreadersAHA News: Are Virtual Doctor Visits Safe for Discharged Heart Failure Patients?Double Lung Transplants Save Lives of Sickest COVID PatientsGynecological Cancers Not a Risk for Severe COVID-19: Study11 States Could Face ICU Doc Shortages as Coronavirus Cases SurgeWildfire Pollution Puts Kidney Patients at RiskAmerica's Progress Against Early Cardiovascular Death Is SlowingAHA News: 5 Easy Ways to Keep Tabs on Heart HealthGene Study Shows How Coronavirus Swept Through the Diamond PrincessOne Disease Mosquitoes Don't Spread: CoronavirusU.S. Coronavirus Death Toll Surges Past 150,000Do Bedbugs Dirty the Air Inside Your Home?AHA News: New Test May Predict Who Develops Certain Type of Heart FailureLess Smoking, Drinking Means Fewer Hip Fractures for AmericansYet Another Study Finds Vaccines Are SafeCommon Diabetes Meds Linked to Higher Odds for a Serious ComplicationSurvivors' COVID Antibodies May Provide a Powerful GiftConcussion Ups Odds for Many Brain ConditionsFinal Coronavirus Vaccine Trials Get UnderwayAHA News: Flu Shot May Help Protect Vulnerable Hospital Patients From Heart Attack, Mini-StrokeCOVID-19 'Super Spreaders' Quickly Fill Room With Virus -- But Masks HelpIn Rush to Publish, Most COVID-19 Research Isn't Reliable, Experts SayGlaucoma Checkups Fall by the Wayside During PandemicLab-Created Virus Can Help COVID-19 Research, Developers SayHow to Counter the Anti-Mask Backlash? Empathy.States With Soaring COVID Cases Must Take Action, U.S. Health Officials SayWhat Puts You at High Risk of Midlife Mental Decline?AHA News: Controlling Diabetes Takes on Greater Urgency During COVID-19 PandemicMany U.S. Homes Too Cramped to Stop COVID-19's SpreadCDC Issues Call to Reopen America's Schools This FallMore Layers Are Better With Homemade Face MasksWith Safety Steps, Moms Unlikely to Pass COVID-19 to Newborns: StudyU.S. Coronavirus Cases Pass 4 Million, Third Day of Over 1,000 Deaths LoggedChronic Conditions Tied to Severe COVID-19 More Common in Southeast, Rural AreasSteroids Other Than Dexamethasone May Also Help Battle COVID-19COVID-19 Jitters Shouldn't Keep You From the Emergency RoomExpert Tips to Help You Beat the HeatEven Mild Obesity Raises Odds for Severe COVID-19U.S. Coronavirus Cases Near 4 Million as Death Toll Tops 1,000 for Second DayAntibodies Fade a Few Weeks After Mild COVID-19, Study FindsEarly Dialysis Doesn't Improve Outcomes With Acute Kidney FailureFor Cancer Patients, Getting COVID-19 Raises Death Risk 16-FoldStraight Talk From Front-Line Experts on Wearing a MaskCoronavirus Death Toll Tops 1,000 as Trump Warns the Worst is Still to ComeThyroid Drug May Not Help After Heart Attack: Study
Questions and AnswersLinks
Related Topics

Diabetes

AHA News: New Test May Predict Who Develops Certain Type of Heart Failure


HealthDay News
Updated: Jul 28th 2020

new article illustration

TUESDAY, July 28, 2020 (American Heart Association News) -- People with higher levels of a specific inflammatory marker may have a greater risk of developing a form of heart failure, according to new research that could help predict who might develop the disease.

The biomarker, called GlycA, is an indicator of inflammation throughout the body. Inflammation is thought to play a pivotal role in heart failure, a chronic condition when the heart muscle doesn't pump as well as it should. It affects an estimated 6.2 million U.S. adults.

The new study, published Tuesday in the American Heart Association journal Circulation: Heart Failure, sought to find out if high levels of GlycA in the blood might predict two subsets of heart failure: heart failure that occurs despite having a preserved – or normal – ejection fraction, and heart failure that occurs with a reduced ejection fraction. Ejection fraction refers to how much blood the left ventricle pumps out into the body.

Researchers studied about 14 years' worth of data from 6,507 middle-age and older people who did not have cardiovascular disease or heart failure at the start of the study. After accounting for various factors – including high blood pressure and diabetes – researchers discovered people with the highest levels of GlycA had more than double the risk of developing heart failure with preserved ejection fraction compared to those with the lowest levels. However, having higher biomarker levels did not impact the risk of developing the other subtype – heart failure with reduced ejection fraction.

Preserved ejection fraction is when the heart contracts normally but the left ventricle doesn't relax properly. Reduced ejection fraction is when the heart muscle does not contract effectively.

"They're really two different entities, so one (treatment) approach doesn't fit all," said Dr. Erin Michos, the study's senior author.

The study's findings are particularly important, she said, because treating preserved ejection fraction is more difficult than treating reduced ejection fraction.

"We don't really have any good therapies for heart failure with preserved ejection fraction," said Michos, associate director of preventive cardiology at the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease in Baltimore. "The best intervention is trying to prevent it from happening in the first place through maintaining a normal weight, exercising, eating a healthy diet and controlling blood pressure and blood glucose."

Since the study was observational, "we can't show that the inflammation actually directly caused the heart failure," she said. "Maybe having much inflammation in the body is just a marker of someone who's sicker in general."

Still, Michos said she'd like to see GlycA testing become more routine. She also called for future research to delve into whether heart failure can be prevented by lowering GlycA levels.

Dr. Ferhaan Ahmad, who was not involved in the research, called it a "novel" study that offers a new way to predict who might develop heart failure with preserved ejection fraction.

"It's a perplexing disorder about which not much is understood. The contractile function of the heart appears to be normal, and yet patients still have pretty severe heart failure symptoms," said Ahmad, director of the Cardiovascular Genetics Program at the University of Iowa in Iowa City.

Figuring out what causes heart failure with preserved ejection fraction will be extremely challenging, he said. But at least the new study gives doctors something to work with.

"The big takeaway is that this may be a superior method to identify patients at higher risk of this pretty intractable disease," Ahmad said. "And then we can intervene early to reduce the risk factors we know already – obesity, diabetes, hypertension. If we can target those, we can reduce the future risk of developing the disease."